DRUGphase2small molecule
reldesemtiv
Mechanism
Fast skeletal muscle troponin activator. Enhances muscle force production.
Related claims (9)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| protein interaction | Reldesemtiv binding interactions with troponin include conventional hydrogen bonds, carbon hydrogen bonds, pi-alkyl, pi-sulfur and halogen interactions. | 59% | 36959428 |
| protein interaction | Reldesemtiv binding to the fast skeletal troponin complex induces conformational compacting of troponin C characterized by reduced solvent exposure. | 59% | 36959428 |
| protein interaction | Reldesemtiv binding to troponin C sensitizes the protein to calcium through conformational changes that favor slow calcium ion release. | 53% | 36959428 |
| protein interaction | Arg113, Met116, Val114, and Met121 in the switch region of the inhibitory troponin subunit are critical residues for Reldesemtiv binding and contribute substantially to binding free energy. | 53% | 36959428 |
| drug efficacy | Reldesemtiv is proposed as a potential treatment for neurogenic neuromuscular diseases including spinal muscular atrophy by increasing muscle strength through troponin activation. | 53% | 36959428 |
| drug target | Reldesemtiv is a second-generation small molecule developed to activate fast skeletal muscle troponin complex with improved specificity and reduced off-target effects. | 53% | 36959428 |
| drug efficacy | The change from baseline in 6MWD was greater for reldesemtiv 450 mg than for placebo at weeks 4 and 8 (clinical trial result). | 51% | 33624184 |
| drug efficacy | Changes from baseline in MEP at week 8 on reldesemtiv 150 and 450 mg were significantly greater than those on placebo (clinical trial result). | 51% | 33624184 |
| drug efficacy | Results suggest reldesemtiv may offer clinical benefit (clinical trial result). | 45% | 33624184 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.